Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, alzheimer"s disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
Website: neurocrine.com


  • Good financial results growth rate 176.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (37.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -7.1% (LTM)
  • Share price is 76.3% higher than minimum and 4.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.1x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $3.0 mln (-0.020% of cap.)

Key Financials (Download financials)

Ticker: NBIX
Share price, USD:  (-1.8%)154.35
year average price 136.85  


year start price 122.96 2025-05-20

min close price 119.12 2025-05-22

max close price 160.77 2026-05-13

current price 154.35 2026-05-20
Common stocks: 95 800 000

Dividend Yield:  0.0%
FCF Yield LTM: -7.1%
EV / LTM EBITDA: 13.1x
EV / EBITDA annualized: 5.4x
Last revenue growth (y/y):  +200.0%
Last growth of EBITDA (y/y):  +152.6%
Historical revenue growth:  +38.6%
Historical growth of EBITDA:  +36.1%
EV / Sales: 3.1x
Margin (EBITDA LTM / Revenue): 23.9%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 15 061
Net Debt ($m): -298
EV (Enterprise Value): 14 763
EBITDA LTM (млн $): 1 126
EV / LTM EBITDA: 13.1x
Price to Book: 5.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-26prnewswire.com

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

2026-01-22zacks.com

Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive?

2026-01-21prnewswire.com

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

2025-12-22reuters.com

Neurocrine's movement disorder treatment fails late-stage trial

2025-12-16seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript

2025-12-02seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

2025-11-27zacks.com

Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now

2025-11-11zacks.com

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

2025-10-28seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript

2025-10-28zacks.com

Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 795M 688M 2 355M 622M 590M 515M 1 887M 499M 453M 420M 1 489M 388M 1 134M 1 046M
costOfRevenue 14M 11M 34M 8M 16M 13M 40M 11M 12M 9M 23M 6M 14M 10M
grossProfit 781M 676M 2 321M 614M 575M 502M 1 847M 488M 441M 412M 1 466M 382M 1 119M 1 036M
grossProfitRatio 0.982 0.984 0.987 0.974 0.975 0.978 0.975 0.98 0.984
researchAndDevelopmentExpenses 250M 244M 731M 195M 185M 154M 565M 142M 146M 140M 464M 108M 328M 275M
generalAndAdministrativeExpenses 0 0 816M 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 191M 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 292M 286M 1 007M 234M 242M 243M 888M 204M 222M 243M 753M 186M 583M 433M
otherExpenses 300 000 0 13M 1 000 000 3M -89M 144M 0 0 144M 0 0 105M 165M
operatingExpenses 542M 531M 1 751M 430M 427M 397M 1 597M 346M 368M 382M 1 217M 294M 1 017M 873M
costAndExpenses 556M 542M 1 785M 438M 442M 410M 1 636M 358M 379M 391M 1 240M 300M 1 031M 883M
interestIncome 22M 21M 91M 0 0 0 0 16M 0 0 11M 0 0 0
interestExpense 0 0 127M 0 0 1M 5M 1M 1M 1M 7M 1M 26M 33M
depreciationAndAmortization 8M 7M 27M 7M 7M 6M 21M 6M 5M 144M 16M 4M 11M 9M
ebitda 300M 153M 640M 191M 155M 112M 416M 141M 74M 30M 265M 92M 138M 148M
ebitdaratio 0.377 0.222 0.308 0.263 0.216 0.283 0.163 0.071 0.237
operatingIncome 239M 146M 571M 184M 148M 105M 251M 141M 74M -114M 249M 88M 103M 163M
operatingIncomeRatio 0.301 0.212 0.295 0.251 0.204 0.283 0.163 -0.272 0.226
totalOtherIncomeExpensesNet 53M 14M -85M 7M -47M -71M 81M -25M 49M 11M -35M 10M -1M -56M
incomeBeforeTax 292M 160M 486M 190M 99M 35M 332M 116M 122M -103M 214M 98M 101M 107M
incomeBeforeTaxRatio 0.367 0.232 0.306 0.167 0.067 0.232 0.269 -0.246 0.252
incomeTaxExpense 82M 52M 145M 61M 34M -9M 82M 33M 26M -27M 59M 29M 12M -301M
netIncome 210M 108M 341M 130M 65M 43M 250M 83M 96M -77M 155M 69M 90M 407M
netIncomeRatio 0.264 0.156 0.209 0.11 0.084 0.167 0.211 -0.182 0.177
eps 2.11 1.09 3.4 1.28 0.64 0.43 2.56 0.85 0.98 -0.79 1.61 0.72 0.95 4.37
epsdiluted 2.04 1.06 1.24 0.63 0.42 0.82 0.95 -0.79 0.69
weightedAverageShsOut 99M 99M 100M 101M 101M 100M 98M 98M 98M 97M 96M 96M 95M 93M
weightedAverageShsOutDil 103M 101M 104M 104M 104M 104M 101M 101M 100M 97M 99M 99M 98M 98M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -36M -5M 4M -26M -33M
ebit 613M 395M 249M 127M 140M
nonOperatingIncomeExcludingInterest -42M -144M 0 -25M 24M
netIncomeFromContinuingOperations 341M 250M 155M 90M 407M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 341M 250M 155M 90M 407M
epsDiluted 3.29 2.47 1.56 0.92 4.16

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 340M 264M 233M 349M 140M 396M 251M 294M 160M -90M 263M 212M 341M 187M
shortTermInvestments 775M 712M 843M 879M 899M 814M 781M 801M 817M 1 139M 726M 587M 371M 614M
cashAndShortTermInvestments 1 115M 976M 1 076M 1 228M 1 039M 1 211M 1 032M 1 095M 977M 895M 989M 799M 711M 801M
netReceivables 728M 596M 479M 481M 468M 451M 439M 418M 388M 392M 350M 301M 186M 157M
inventory 69M 57M 57M 46M 43M 37M 38M 29M 32M 33M 35M 37M 31M 28M
otherCurrentAssets 246M 121M 112M 122M 120M 101M 98M 555M 520M 538M 79M 68M 46M 30M
totalCurrentAssets 2 158M 1 749M 1 725M 1 877M 1 670M 1 799M 1 607M 1 650M 1 497M 1 433M 1 454M 1 206M 973M 1 016M
propertyPlantEquipmentNet 566M 584M 592M 337M 343M 346M 347M 150M 149M 147M 146M 151M 156M 127M
goodwill 0 0 6M 0 6M 0 0 0 0 0 0 0 0 0
intangibleAssets 36M 37M 37M 35M 34M 34M 36M 35M 37M 37M 37M 0 0 0
goodwillAndIntangibleAssets 36M 37M 42M 35M 34M 34M 36M 35M 37M 37M 37M 0 0 0
longTermInvestments 118M 961M 864M 771M 789M 872M 849M 588M 516M 380M 402M 458M 624M 265M
taxAssets 369M 537M 486M 454M 420M 378M 363M 383M 379M 337M 306M 319M 315M 319M
otherNonCurrentAssets 1 019M 22M 10M 62M 50M 43M 50M 43M 36M 25M 25M 11M 4M 6M
totalNonCurrentAssets 2 107M 2 141M 1 994M 1 658M 1 635M 1 673M 1 644M 1 198M 1 117M 927M 915M 938M 1 100M 719M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 4 266M 3 890M 3 719M 3 535M 3 305M 3 472M 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M 2 073M 1 735M
accountPayables 120M 105M 110M 96M 107M 87M 133M 94M 0 0 67M 0 52M 39M
shortTermDebt 0 0 0 0 35M 294M 170M 170M 170M 0 169M 169M 0 0
taxPayables 0 26M 0 0 35M 25M 24M 73M 0 0 9M 0 0 0
deferredRevenue 0 0 0 0 0 25M 0 -94M 0 0 0 0 0 0
otherCurrentLiabilities 518M 416M 298M 334M 221M 307M 261M 522M 413M 374M 225M 316M 133M 91M
totalCurrentLiabilities 638M 546M 508M 430M 399M 713M 655M 692M 583M 374M 538M 485M 246M 187M
longTermDebt 428M 439M 0 251M 256M 253M 0 86M 89M 260M 0 97M 335M 318M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 196M 210M 166M 135M 141M 121M 106M 69M 89M 41M 30M -56M 12M 10M
totalNonCurrentLiabilities 624M 649M 621M 386M 397M 373M 365M 155M 178M 301M 123M 114M 453M 422M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 439M 455M 251M 292M 253M 258M 86M 89M 90M 94M 97M 105M 94M
totalLiabilities 1 262M 1 196M 1 129M 816M 796M 1 086M 1 019M 846M 760M 675M 661M 599M 699M 609M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings 294M 85M 29M 81M -49M -114M -157M -305M -388M -483M -407M -496M -636M -725M
accumulatedOtherComprehensiveIncomeLoss 13M 13M 6M 15M 3M 3M 7M -2M -1M -3M -8M -14M -2M 2M
othertotalStockholdersEquity 2 696M 2 597M 2 623M 2 555M 2 496M 2 309M 2 242M 2 171M 2 054M
totalStockholdersEquity 3 004M 2 694M 2 590M 2 719M 2 509M 2 386M 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M 1 374M 1 126M
totalEquity 3 004M 2 694M 2 590M 2 719M 2 509M 2 386M 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M 1 374M 1 126M
totalLiabilitiesAndStockholdersEquity 4 266M 3 890M 3 535M 3 305M 3 472M 2 848M 2 613M 2 360M 2 143M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 266M 3 890M 3 719M 3 535M 3 305M 3 472M 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M 2 073M 1 735M
totalInvestments 893M 1 673M 1 707M 1 650M 1 689M 1 686M 1 630M 934M 990M 1 139M 1 128M 1 045M 995M 879M
totalDebt 428M 439M 455M 251M 292M 547M 428M 256M 259M 260M 263M 266M 440M 412M
netDebt 88M 175M 222M -98M 152M 151M 177M -38M 99M 350M 0 54M 100M 225M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 479M 439M 350M 186M 157M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 110M 133M 76M 52M 39M
otherPayables 0 0 9M 0 0
accruedExpenses 100M 90M 67M 61M 57M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 455M 258M 94M 105M 94M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 555M 2 382M 2 122M 2 011M 1 850M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 210M 108M 341M 130M 65M 43M 250M 83M 96M -77M 155M 69M 90M 407M
depreciationAndAmortization 8M 7M 27M 7M 7M 6M 21M 6M 5M 5M 16M 4M 11M 9M
deferredIncomeTax 168M -37M -123M -35M -41M -16M -57M -4M -42M -32M 19M 9M 4M -311M
stockBasedCompensation 54M 53M 196M 42M 43M 45M 194M 48M 69M 40M 173M 43M 134M 100M
changeInWorkingCapital 63M -39M -19M 4M -86M -32M 28M 46M 93M -58M -67M -16M 17M -38M
accountsReceivables -132M -80M -40M -13M -18M -11M -89M -30M 4M -42M -162M -22M -28M -31M
inventory -12M 2M -19M -3M -5M 1M 5M 3M 2M 2M -3M -8M -3M -11M
accountsPayables 56M 16M 29M 39M -60M -19M 64M 124M 16M 7M 115M 0 57M 27M
otherWorkingCapital 152M 23M 11M -19M -4M -3M 48M -51M 71M -24M -17M 14M -9M -24M
otherNonCashItems -275M 11M 174M 11M 217M 169M -47M 34M -41M -4M 45M -10M 800 000 61M
netCashProvidedByOperatingActivities 228M 102M 595M 158M 65M 130M 390M 212M 180M -125M 339M 99M 257M 229M
investmentsInPropertyPlantAndEquipment -13M -13M -38M -8M -12M -11M -28M -8M -7M -9M -17M 0 -23M -11M
acquisitionsNet 0 0 0 0 0 0 0 90M 7M -2M -43M 0 0 0
purchasesOfInvestments -409M -315M -1 056M -233M -192M -320M -1 411M -363M -324M -238M -629M -134M -805M -736M
salesMaturitiesOfInvestments 225M 299M 968M 265M 175M 276M 972M 273M 205M 204M 511M 71M 698M 751M
otherInvestingActivites 0 0 0 -17M -44M -90M -7M 2M 2M
netCashUsedForInvestingActivites -197M -29M 25M -28M -55M -97M -126M -42M -61M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 46M 14M 26M 16M 70M 19M 0 8M 0
commonStockRepurchased 0 -18M -300M 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 26M -309M 70M 19M 0 0 11M
netCashUsedProvidedByFinancingActivities 46M -3M 26M -293M 70M 19M 3M 8M 11M
effectOfForexChangesOnCash -200 000 200 000 0 300 000 0 0 300 000 0 0 0 -1M 0 0 0
netChangeInCash 76M 70M -18M 217M -257M 145M -12M 134M 57M -159M -73M 49M 154M 75M
cashAtEndOfPeriod 348M 272M 241M 357M 140M 396M 259M 302M 168M 112M 271M 220M 344M 190M
cashAtBeginningOfPeriod 272M 202M 259M 140M 396M 251M 271M 168M 112M 271M 344M 171M 190M 116M
operatingCashFlow 228M 102M 595M 158M 65M 130M 390M 212M 180M -125M 339M 99M 257M 229M
capitalExpenditure -13M -13M -38M -8M -12M -11M -28M -8M -7M -9M -17M 0 -23M -11M
freeCashFlow 214M 90M 557M 150M 53M 119M 362M 204M 173M -134M 323M 99M 233M 218M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -127M -467M -177M -130M 4M
netDebtIssuance -309M 0 -279M -100 000 -187M
longTermNetDebtIssuance -309M 0 -279M -100 000 -187M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -178M 65M 45M 28M 29M
netCommonStockIssuance -178M 65M 45M 28M 29M
commonStockIssuance 122M 65M 45M 28M 29M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 0
netCashProvidedByFinancingActivities -487M 65M -234M 27M -158M
incomeTaxesPaid 218M 52M 14M 5M 15M
interestPaid 2M 4M 7M 9M 12M

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-05-05 ET (fiscal 2025 q1)
2024 q4
2025-02-06 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-06 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-02-11 21:01 ET
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
2026-01-26 13:30 ET
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
2026-01-15 13:30 ET
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
2026-01-05 21:01 ET
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-22 21:05 ET
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
2025-12-16 21:01 ET
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
2025-12-09 21:01 ET
Neurocrine Biosciences to Host R&D Day on December 16
2025-11-20 13:30 ET
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
2025-11-11 21:01 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences
2025-11-10 21:05 ET
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
2025-10-28 20:01 ET
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
2025-10-17 ET
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
2025-10-07 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
2025-10-06 ET
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
2025-10-06 ET
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
2025-09-23 ET
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
2025-09-22 ET
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
2025-09-16 ET
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
2025-08-26 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2025-08-06 ET
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
2025-07-30 ET
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
2025-07-15 ET
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
2025-07-15 ET
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
2025-07-14 ET
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
2025-07-14 ET
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
2025-07-09 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
2025-06-30 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
2025-06-27 ET
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
2025-06-20 ET
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
2025-06-09 ET
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
2025-06-02 ET
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
2025-05-28 ET
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
2025-05-16 ET
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
2025-05-16 ET
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
2025-05-15 ET
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
2025-05-14 ET
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
2025-05-08 ET
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
2025-05-06 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
2025-05-06 ET
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
2025-05-05 ET
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
2025-05-05 ET
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
2025-04-30 ET
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
2025-04-24 ET
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
2025-04-14 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
2025-04-04 ET
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
2025-03-31 ET
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
2025-03-20 ET
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
2025-03-17 ET
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
2025-03-11 ET
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
2025-03-05 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2025-02-27 ET
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
2025-02-25 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
2025-02-21 ET
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
2025-02-06 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
2025-01-30 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
2025-01-28 ET
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
2025-01-27 ET
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
2025-01-23 ET
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
2025-01-21 ET
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
2025-01-08 ET
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
2025-01-06 ET
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-20 ET
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
2024-12-13 ET
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
2024-11-26 ET
Neurocrine Biosciences to Participate at Investor Conferences in December
2024-11-07 ET
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
2024-11-05 ET
Neurocrine Biosciences to Participate at Investor Conferences in November
2024-11-04 ET
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
2024-11-04 ET
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
2024-10-30 11:00 ET
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
2024-10-09 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
2024-09-30 12:30 ET
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
2024-09-19 20:01 ET
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
2024-09-12 20:05 ET
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
2024-09-10 20:01 ET
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
2024-08-28 20:05 ET
Neurocrine Biosciences to Participate at Investor Conferences in September
2024-08-28 11:00 ET
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
2024-08-07 20:01 ET
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
2024-08-01 11:00 ET
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
2024-07-18 12:30 ET
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
2024-07-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
2024-07-01 11:30 ET
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
2024-06-03 12:01 ET
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
2024-06-03 11:30 ET
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
2024-05-29 20:01 ET
Neurocrine Biosciences to Participate at Investor Conferences in June
2024-05-28 20:14 ET
Neurocrine Biosciences Announces CEO Succession Plan
2024-05-28 12:30 ET
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
2024-05-21 20:05 ET
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
2024-05-14 12:30 ET
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
2024-05-09 13:45 ET
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
2024-05-08 12:30 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
2024-05-07 20:15 ET
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
2024-05-07 12:30 ET
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
2024-05-06 12:30 ET
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
2024-05-03 17:15 ET
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
2024-05-01 11:00 ET
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
2024-04-30 21:12 ET
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
2024-04-24 12:30 ET
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
2024-04-23 11:00 ET
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
2024-04-16 20:01 ET
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
2024-04-10 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
2024-04-03 12:30 ET
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
2024-03-28 12:30 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2024-03-11 20:01 ET
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
2024-02-27 21:01 ET
Neurocrine Biosciences to Participate at Investor Conferences in March
2024-02-07 12:00 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
2024-01-17 21:16 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
2024-01-02 21:01 ET
Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 21:01 ET
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
2023-12-01 12:00 ET
Neurocrine Biosciences to Host Analyst Day on December 5, 2023
2023-11-13 12:00 ET
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
2023-11-09 21:01 ET
Neurocrine Biosciences Provides Development Pipeline Update
2023-11-08 21:05 ET
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
2023-11-08 21:01 ET
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
2023-11-02 12:30 ET
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
2023-10-31 11:00 ET
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-10-10 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
2023-10-05 11:00 ET
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
2023-09-21 13:15 ET
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
2023-09-14 12:30 ET
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
2023-09-12 11:30 ET
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
2023-09-11 23:01 ET
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-09-11 12:30 ET
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-08-31 20:01 ET
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2023-08-29 12:30 ET
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine)...
2023-08-28 12:30 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
2023-08-18 20:34 ET
Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
2023-08-01 11:00 ET
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-07-11 20:05 ET
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
2023-07-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
2023-06-15 12:30 ET
Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023
2023-06-08 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-02 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
2023-05-19 12:30 ET
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
2023-05-15 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Soc...
2023-05-12 12:30 ET
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
2023-05-03 11:30 ET
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
2023-05-02 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
2023-05-01 12:30 ET
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
2023-04-12 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results
2023-03-21 20:01 ET
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
2023-03-09 21:30 ET
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
2023-03-09 13:30 ET
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
2023-03-08 21:01 ET
Neurocrine Biosciences to Participate at Investor Conferences in March
2023-03-03 13:30 ET
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting
2023-02-14 21:01 ET
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
2023-02-07 21:01 ET
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference
2023-02-06 12:30 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
2023-01-17 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results
2023-01-09 12:00 ET
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
2023-01-03 21:01 ET
Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 21:01 ET
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
2022-12-06 21:01 ET
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
2022-12-02 13:30 ET
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
2022-11-08 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2022-11-03 13:00 ET
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
2022-11-03 12:30 ET
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
2022-11-01 11:30 ET
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
2022-10-27 12:30 ET
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
2022-10-24 12:30 ET
Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022
2022-10-19 12:30 ET
Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
2022-10-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
2022-09-29 15:00 ET
Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
2022-09-19 12:30 ET
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022
2022-09-15 12:45 ET
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
2022-09-15 12:30 ET
Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
2022-09-12 12:30 ET
Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners
2022-09-06 20:01 ET
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-04 23:05 ET
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
2022-08-04 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
2022-07-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
2022-06-13 12:00 ET
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
2022-06-08 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-06 13:30 ET
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
2022-06-06 12:30 ET
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
2022-05-25 01:40 ET
Neurocrine Biosciences Announces Repurchase of Convertible Notes
2022-05-23 12:30 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
2022-05-12 23:37 ET
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
2022-05-04 11:30 ET
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
2022-05-03 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
2022-05-02 12:30 ET
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
2022-04-13 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
2022-04-01 12:30 ET
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
2022-03-28 20:36 ET
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
2022-03-28 12:30 ET
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
2022-03-24 12:30 ET
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
2022-03-21 20:01 ET
Neurocrine Biosciences to Present at Stifel 2022 CNS Days
2022-03-01 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2022-02-11 12:30 ET
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
2022-01-25 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
2022-01-06 21:01 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
2022-01-03 21:01 ET
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-07 21:35 ET
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
2021-11-30 21:05 ET
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
2021-11-22 13:00 ET
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
2021-11-09 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2021-11-01 20:01 ET
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
2021-11-01 12:00 ET
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021
2021-10-16 21:00 ET
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
2021-10-11 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
2021-10-08 11:29 ET
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
2021-09-10 13:23 ET
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
2021-09-08 12:30 ET
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
2021-09-02 20:13 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2021-08-05 20:01 ET
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
2021-08-03 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
2021-07-19 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
2021-07-08 20:01 ET
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
2021-06-01 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-11 20:01 ET
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
2021-05-05 20:01 ET
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
2021-05-04 20:01 ET
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference
2021-05-03 12:30 ET
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week
2021-04-26 20:01 ET
Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides
2021-04-16 13:00 ET
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
2021-04-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
2021-04-08 20:01 ET
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
2021-03-25 20:01 ET
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
2021-03-24 22:35 ET
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
2021-03-20 15:00 ET
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
2021-03-09 21:01 ET
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
2021-03-02 12:30 ET
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
2021-02-23 21:01 ET
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference
2021-02-04 21:01 ET
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-02-02 21:01 ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
2021-01-20 21:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
2021-01-08 12:30 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
2021-01-04 21:01 ET
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-22 21:17 ET
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
2020-11-19 14:00 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2020-11-19 13:00 ET
Neurocrine Biosciences Announces Repurchase of Convertible Notes
2020-11-09 21:01 ET
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
2020-11-09 14:00 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2020-10-08 12:00 ET
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
2020-10-06 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
2020-09-28 20:01 ET
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting
2020-09-14 12:44 ET
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
2020-09-11 15:36 ET
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson’s Disease
2020-09-11 15:34 ET
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
2020-09-11 15:32 ET
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
2020-09-08 20:01 ET
Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-03 20:06 ET
Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings
2020-09-02 20:01 ET
Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
2020-08-03 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
2020-07-30 20:01 ET
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
2020-07-13 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
2020-06-16 11:00 ET
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
2020-06-15 20:01 ET
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
2020-06-08 15:01 ET
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
2020-06-04 20:01 ET
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
2020-05-26 20:01 ET
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
2020-05-14 23:29 ET
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
2020-05-13 20:01 ET
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
2020-05-11 20:01 ET
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
2020-05-06 20:01 ET
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
2020-05-05 20:01 ET
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020
2020-04-27 11:30 ET
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
2020-04-15 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
2020-04-03 12:30 ET
Neurocrine Biosciences Provides COVID-19 Business Update
2020-02-25 21:01 ET
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
2020-02-04 21:01 ET
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
2020-02-03 22:00 ET
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
2020-01-20 21:30 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
2020-01-12 23:30 ET
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
2020-01-10 06:00 ET
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
2020-01-06 21:01 ET
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference  Live Audio Webcast will be on January 13, 2020
2019-12-02 12:30 ET
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
2019-11-26 21:01 ET
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference
2019-11-12 21:01 ET
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
2019-11-05 21:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-11-04 21:01 ET
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
2019-10-14 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
2019-10-04 22:00 ET
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
2019-10-01 20:01 ET
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
2019-09-30 20:01 ET
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
2019-09-17 20:11 ET
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
2019-09-11 20:01 ET
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
2019-08-28 20:01 ET
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-08-05 12:30 ET
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
2019-07-29 20:01 ET
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
2019-07-10 20:10 ET
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
2019-07-08 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
2019-06-11 20:01 ET
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
2019-06-04 20:01 ET
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-30 20:01 ET
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
2019-05-16 20:01 ET
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
2019-05-06 12:00 ET
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
2019-05-05 13:05 ET
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
2019-05-05 13:00 ET
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
2019-04-29 20:01 ET
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
2019-04-08 20:01 ET
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
2019-03-28 20:15 ET
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
2019-01-29 12:00 ET
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

SEC forms

Show financial reports only

SEC form 10
2026-02-11 16:03 ET
Neurocrine Biosciences reported for 2025 q4
SEC form 8
2026-02-11 16:02 ET
Neurocrine Biosciences published news for 2025 q4
SEC form 8
2026-02-11 16:02 ET
Neurocrine Biosciences published news for 2025 q4
SEC form 10
2025-10-28 20:03 ET
Neurocrine Biosciences reported for 2025 q3
SEC form 8
2025-10-28 20:02 ET
Neurocrine Biosciences published news for 2025 q3
SEC form 8
2025-10-28 20:02 ET
Neurocrine Biosciences reported for 2025 q3
SEC form 10
2025-07-30 20:04 ET
Neurocrine Biosciences reported for 2025 q2
SEC form 8
2025-07-30 20:02 ET
Neurocrine Biosciences published news for 2025 q2
SEC form 8
2025-07-30 20:02 ET
Neurocrine Biosciences reported for 2025 q2
SEC form 10
2025-05-05 00:00 ET
Neurocrine Biosciences reported for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Neurocrine Biosciences published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Neurocrine Biosciences reported for 2025 q1
SEC form 10
2025-02-10 00:00 ET
Neurocrine Biosciences published news for 2024 q4
SEC form 8
2025-02-06 16:04 ET
Neurocrine Biosciences published news for 2024 q4
SEC form 8
2025-02-06 16:04 ET
Neurocrine Biosciences reported for 2024 q4
SEC form 10
2024-10-30 07:04 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Neurocrine Biosciences published news for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 10
2024-08-01 07:04 ET
Neurocrine Biosciences reported for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Neurocrine Biosciences published news for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Neurocrine Biosciences reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Neurocrine Biosciences published news for 2024 q2
SEC form 10
2024-05-01 07:03 ET
Neurocrine Biosciences reported for 2024 q1
SEC form 8
2024-05-01 07:01 ET
Neurocrine Biosciences published news for 2024 q1
SEC form 8
2024-05-01 07:01 ET
Neurocrine Biosciences reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
Neurocrine Biosciences published news for 2024 q1
SEC form 10
2024-02-09 00:00 ET
Neurocrine Biosciences reported for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 10
2023-10-31 07:02 ET
Neurocrine Biosciences reported for 2023 q3
SEC form 8
2023-10-31 07:01 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-08-01 07:03 ET
Neurocrine Biosciences reported for 2023 q2
SEC form 6
2023-08-01 07:02 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 17:26 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 16:05 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-11 19:04 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 10
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 6
2023-03-28 20:44 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-23 19:14 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-15 19:30 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-10 16:02 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2023-02-09 16:02 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-02-06 07:32 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 8
2023-02-06 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-01-09 07:04 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2022-11-01 16:10 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-11-01 07:31 ET
Neurocrine Biosciences published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-08-30 08:01 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:08 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-08-04 16:05 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-05-31 21:04 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-24 21:44 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-23 16:17 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-05-04 07:39 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-05-04 07:37 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-04-07 17:16 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-02-11 17:11 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-11 07:31 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-09 20:01 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-01-06 16:08 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2021-12-23 08:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-12-01 19:56 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-22 08:01 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 16:05 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-01 16:03 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-08-03 16:03 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-08-03 16:02 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-05-21 16:03 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 16:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-05-05 16:05 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 16:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 09:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-09 17:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-02-05 16:19 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-04 16:05 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-02 16:04 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-01-08 07:32 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2020-11-24 08:02 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-19 08:07 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 10
2020-11-09 16:04 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-09 16:02 ET
Neurocrine Biosciences published news for 2020 q3